In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and ...

Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa ...

Over the course of the study (126 weeks), 75% of patients showed sustained efficacy, achieving 2 points or more of improvement in MG activities of daily living ... the I-RODS scale (>8 points ...

The additional analysis confirmed that patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their Myasthenia Gravis Activities of Daily Living (MG-ADL ...